GLP1R and atrial fibrillation: Further, data on medications such as anti-arrhythmic drugs used directly in the treatment of AF, as well as those such as sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists that may have wider benefits in terms reducing cardiovascular events and AF-related complications, were not available [22,42,43].